Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Health Outcomes
100%
Schizophrenia
100%
Antipsychotics
100%
Olanzapine
100%
Schizophrenia Treatment
100%
Clozapine
100%
Typical Antipsychotics
80%
Atypical Antipsychotics
60%
Quetiapine
60%
Tolerability
40%
Social Functioning
40%
Anxiolytic
40%
Extrapyramidal Symptoms
40%
Quality of Life
20%
Low Risk
20%
Antidepressants
20%
Social Contact
20%
Medication Use
20%
Health-related Quality of Life
20%
Male Patients
20%
Female Patients
20%
European Countries
20%
Weight Gain
20%
Adverse Events
20%
Impotence
20%
Adult Patients
20%
Clinical Severity
20%
Naturalistic Study
20%
Patient Assessment
20%
Routine Clinical Practice
20%
Risperidone
20%
Prolactin
20%
Antipsychotic Use
20%
Patient Recruitment
20%
Clinical Global Impression
20%
Amenorrhea
20%
Loss of Libido
20%
Tardive Dyskinesia
20%
Global Quality
20%
Concomitant Medications
20%
Amisulpride
20%
Clinical Global Impression Scale
20%
Outpatient Treatment
20%
Mood Stabilizers
20%
Neuroscience
Olanzapine
100%
Treatment of Schizophrenia
100%
Clozapine
100%
Typical Antipsychotic
80%
Antipsychotic
80%
Atypical Antipsychotic
60%
Quetiapine
60%
Anxiolytic
40%
Extrapyramidal Symptom
40%
Anticholinergic
40%
Quality of Life
40%
Antidepressant
20%
Prolactin
20%
Risperidone
20%
Tardive Dyskinesia
20%
Hypnotic
20%
Libido Disorder
20%
Mood Stabilizer
20%
Amisulpride
20%
Pharmacology, Toxicology and Pharmaceutical Science
Olanzapine
100%
Clozapine
100%
Antipsychotic
80%
Typical Antipsychotic
80%
Atypical Antipsychotic
60%
Cholinergic Receptor Blocking Agent
60%
Quetiapine
60%
Tolerability
40%
Anxiolytic
40%
Extrapyramidal Symptom
40%
Antidepressant
20%
Adverse Event
20%
Risperidone
20%
Prolactin
20%
Patient Recruitment
20%
Mood Stabilizer
20%
Amisulpride
20%
Hypnotic
20%
Amenorrhea
20%
Libido Disorder
20%
Tardive Dyskinesia
20%